Cargando…

Outcomes in COVID-19 Patients with Pneumonia Treated with High-Flow Oxygen Therapy and Baricitinib—Retrospective Single-Center Study

Background. The aim of the study was to assess the effect of baricitinib on 28-day all-cause mortality and the progression of respiratory failure in patients needing transfer to the intensive care unit (ICU) with COVID-19 pneumonia treated with high-flow oxygen therapy. Methods. This retrospective s...

Descripción completa

Detalles Bibliográficos
Autores principales: Obradović, Dušanka, Popović, Milica, Banjac, Maja, Bulajić, Jelena, Đurović, Vladimir, Urošević, Ivana, Milovančev, Aleksandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053916/
https://www.ncbi.nlm.nih.gov/pubmed/36983910
http://dx.doi.org/10.3390/life13030755
_version_ 1785015527504084992
author Obradović, Dušanka
Popović, Milica
Banjac, Maja
Bulajić, Jelena
Đurović, Vladimir
Urošević, Ivana
Milovančev, Aleksandra
author_facet Obradović, Dušanka
Popović, Milica
Banjac, Maja
Bulajić, Jelena
Đurović, Vladimir
Urošević, Ivana
Milovančev, Aleksandra
author_sort Obradović, Dušanka
collection PubMed
description Background. The aim of the study was to assess the effect of baricitinib on 28-day all-cause mortality and the progression of respiratory failure in patients needing transfer to the intensive care unit (ICU) with COVID-19 pneumonia treated with high-flow oxygen therapy. Methods. This retrospective study included hospitalized patients with COVID-19 pneumonia treated with high-flow oxygen non-invasive ventilation receiving standard of care (SOC) or SOC in addition to baricitinib. Data on patients’ characteristics, pro-inflammatory markers, D dimer, and National Early Warning Score 2 (NEWS2) values were collected and compared between groups. The primary endpoint was 28-day all-cause in-hospital mortality and the secondary outcome was transfer to the ICU. Results. The study included 125 patients. The primary outcome was observed in 44.8% of them: 27% in the baricitinib group vs. 62% in the SOC group, p < 0.001. Transfer to the ICU ward was significantly lower in the baricitinib group: 29% vs. 81%, p < 0.001. A significant improvement was observed when the baricitinib group was compared to SOC in procalcitonin, CRP, D-dimer, neutrophil-to-lymphocyte ratio values, and NEWS2. Conclusion. Treatment with baricitinib in addition to SOC was associated with reduced mortality and a lower prevalence of transfer to the ICU in hospitalized patients with COVID-19 pneumonia treated with high-flow oxygen non-invasive therapy.
format Online
Article
Text
id pubmed-10053916
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100539162023-03-30 Outcomes in COVID-19 Patients with Pneumonia Treated with High-Flow Oxygen Therapy and Baricitinib—Retrospective Single-Center Study Obradović, Dušanka Popović, Milica Banjac, Maja Bulajić, Jelena Đurović, Vladimir Urošević, Ivana Milovančev, Aleksandra Life (Basel) Article Background. The aim of the study was to assess the effect of baricitinib on 28-day all-cause mortality and the progression of respiratory failure in patients needing transfer to the intensive care unit (ICU) with COVID-19 pneumonia treated with high-flow oxygen therapy. Methods. This retrospective study included hospitalized patients with COVID-19 pneumonia treated with high-flow oxygen non-invasive ventilation receiving standard of care (SOC) or SOC in addition to baricitinib. Data on patients’ characteristics, pro-inflammatory markers, D dimer, and National Early Warning Score 2 (NEWS2) values were collected and compared between groups. The primary endpoint was 28-day all-cause in-hospital mortality and the secondary outcome was transfer to the ICU. Results. The study included 125 patients. The primary outcome was observed in 44.8% of them: 27% in the baricitinib group vs. 62% in the SOC group, p < 0.001. Transfer to the ICU ward was significantly lower in the baricitinib group: 29% vs. 81%, p < 0.001. A significant improvement was observed when the baricitinib group was compared to SOC in procalcitonin, CRP, D-dimer, neutrophil-to-lymphocyte ratio values, and NEWS2. Conclusion. Treatment with baricitinib in addition to SOC was associated with reduced mortality and a lower prevalence of transfer to the ICU in hospitalized patients with COVID-19 pneumonia treated with high-flow oxygen non-invasive therapy. MDPI 2023-03-10 /pmc/articles/PMC10053916/ /pubmed/36983910 http://dx.doi.org/10.3390/life13030755 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Obradović, Dušanka
Popović, Milica
Banjac, Maja
Bulajić, Jelena
Đurović, Vladimir
Urošević, Ivana
Milovančev, Aleksandra
Outcomes in COVID-19 Patients with Pneumonia Treated with High-Flow Oxygen Therapy and Baricitinib—Retrospective Single-Center Study
title Outcomes in COVID-19 Patients with Pneumonia Treated with High-Flow Oxygen Therapy and Baricitinib—Retrospective Single-Center Study
title_full Outcomes in COVID-19 Patients with Pneumonia Treated with High-Flow Oxygen Therapy and Baricitinib—Retrospective Single-Center Study
title_fullStr Outcomes in COVID-19 Patients with Pneumonia Treated with High-Flow Oxygen Therapy and Baricitinib—Retrospective Single-Center Study
title_full_unstemmed Outcomes in COVID-19 Patients with Pneumonia Treated with High-Flow Oxygen Therapy and Baricitinib—Retrospective Single-Center Study
title_short Outcomes in COVID-19 Patients with Pneumonia Treated with High-Flow Oxygen Therapy and Baricitinib—Retrospective Single-Center Study
title_sort outcomes in covid-19 patients with pneumonia treated with high-flow oxygen therapy and baricitinib—retrospective single-center study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053916/
https://www.ncbi.nlm.nih.gov/pubmed/36983910
http://dx.doi.org/10.3390/life13030755
work_keys_str_mv AT obradovicdusanka outcomesincovid19patientswithpneumoniatreatedwithhighflowoxygentherapyandbaricitinibretrospectivesinglecenterstudy
AT popovicmilica outcomesincovid19patientswithpneumoniatreatedwithhighflowoxygentherapyandbaricitinibretrospectivesinglecenterstudy
AT banjacmaja outcomesincovid19patientswithpneumoniatreatedwithhighflowoxygentherapyandbaricitinibretrospectivesinglecenterstudy
AT bulajicjelena outcomesincovid19patientswithpneumoniatreatedwithhighflowoxygentherapyandbaricitinibretrospectivesinglecenterstudy
AT đurovicvladimir outcomesincovid19patientswithpneumoniatreatedwithhighflowoxygentherapyandbaricitinibretrospectivesinglecenterstudy
AT urosevicivana outcomesincovid19patientswithpneumoniatreatedwithhighflowoxygentherapyandbaricitinibretrospectivesinglecenterstudy
AT milovancevaleksandra outcomesincovid19patientswithpneumoniatreatedwithhighflowoxygentherapyandbaricitinibretrospectivesinglecenterstudy